Navigation Links
Trillium and Biogen Idec enter into global license agreement
Date:1/12/2010

biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcyRlla-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Trillium Strengthens its Board of Directors
3. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
4. Biogenerics Will Save Billions, Says Hospira CEO
5. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
6. Icahn Confirms Intention to Nominate Three Directors at Biogen
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
9. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... to Date Examined 175,000 Teenage Girls and Adult ... before motherhood,more than doubled in six years among ... study published in the May issue of Diabetes ... looked exclusively at gestational diabetes,(diabetes that develops during ...
... N.J., April 25 Osteotech, Inc.,(Nasdaq: OSTE ), ... for,regenerative medicine, announced today that the United States Food ... the Plexur,P(TM) Biocomposite for use in spinal applications as ... Previously, Osteotech received FDA clearance for,Plexur P(TM) for use ...
... Inc. (Amex: IMA ), a leading manufacturer ... and professional markets, announced,today that it will attend ... held April 30 - May 2, 2008, at ... Executive Officer, will,attend. His presentation is scheduled for ...
Cached Biology Technology:Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 2Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine 3
(Date:4/24/2014)... Have you ever accidently missed a red light or ... a visible event that you passed by but totally ... for our attention, we can only be aware of ... Beckman Institute Postdoctoral Fellow at the University of Illinois. ... concentrating on obeying traffic signals." , But say there,s ...
(Date:4/24/2014)... attack plants, they often inject harmful proteins into ... natural defenses. However, in some plants, bacteria attack ... potential host. Now, researchers at the University of ... allows the bacteriaknown mostly for attacking tomatoesto invade ... anti-infective treatments that work with food-producing plants to ...
(Date:4/24/2014)... Alison Allan, PhD, a scientist at Western University and ... often spreads or metastasizes to the lung. , Breast ... number two cause of cancer-related deaths among women in ... radiation have a high success rate, but once the ... In particular, the lung is one of the most ...
Breaking Biology News(10 mins):Controlling brain waves to improve vision 2Controlling brain waves to improve vision 3Plants send out signals attracting harmful bacteria, MU study finds 2New study helps to explain why breast cancer often spreads to the lung 2
... The American Association for Cancer Research will host its ... Disparities from Sept. 18-21, 2011, in the Grand Hyatt ... will bring together scientists, survivors, doctors and others to ... treatment methods to better meet the needs of underserved ...
... have employed pheromone-baited bucket traps, canines to sniff out ... to eradicate the coconut rhinoceros beetle (CRB) on Guam ... to these tactics. USDA has given Guam an infusion ... rhino beetle population on island. Aubrey Moore, entomologist and ...
... of American Societies for Experimental Biology (FASEB) announced today ... (HCS). The executive leadership has retained FASEB to ... membership marketing, recruitment, and retention, as well as a ... William Stahl, PhD commented, "HCS is pleased to have ...
Cached Biology News:AACR to host conference on the science of cancer health disparities 2